The national and subnational prevalence and burden of age-related macular degeneration in China by Song, Peige et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The national and subnational prevalence and burden of age-
related macular degeneration in China
Citation for published version:
Song, P, Du, Y, Chan, KY, Theodoratou, E & Rudan, I 2017, 'The national and subnational prevalence and
burden of age-related macular degeneration in China' Journal of Global Health, vol. 7, no. 2, pp. 020703.
DOI: 10.7189/jogh.07.020703
Digital Object Identifier (DOI):
10.7189/jogh.07.020703
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Global Health
Publisher Rights Statement:
Copyright © 2017 by the Journal of Global Health. All rights reserved.
This work is licensed under a Creative Commons Attribution 4.0 International License.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
V
IE
W
PO
IN
TS
PA
PE
RS
journal of
health
global
Peige Song, Yuhang Du, 
Kit Yee Chan, Evropi 
Theodoratou, Igor Rudan; 
on behalf of the Global 
Health Epidemiology 
Research Group (GHERG)
Centre for Global Health Research, 
Usher Institute of Population 
Health Sciences and Informatics, 
University of Edinburgh, Edinburgh, 
Scotland, United Kingdom
Correspondence to:
Peige Song 
Centre for Global Health Research 
Usher Institute of Population Health 
Sciences and Informatics 
University of Edinburgh 
Edinburgh EH8 9AG 
United Kingdom 
p.song@sms.ed.ac.uk
The national and subnational prevalence and 
burden of age–related macular degeneration in 
China
Background Age–related macular degeneration (AMD) is the third most com-
mon cause of blindness, and the fourth leading cause of visual impairment world-
wide, but little is known about the burden of this disease in the most populous 
country–China. This study provides the first comprehensive estimates of the 
prevalence and burden of AMD in China from 1990 to 2015, with projections 
till 2050.
Methods In this study, a systematic review and meta–analysis was conducted to 
estimate the prevalence of AMD in China. China National Knowledge Infrastruc-
ture (CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM–
SinoMed), PubMed, Embase and Medline were searched before September 2016. 
Multilevel mixed–effect meta–regression was performed to define the prevalence 
rates of AMD and its subtypes. UN population data were used to estimate and 
project the number of people affected from 1990 to 2050. Based on different de-
mographic and geographic features, the national burden of AMD in 2000 and 
2010 was distributed to different regions in China.
Results Our search returned 2016 citations, of which 25 met the inclusion cri-
teria. The prevalence of any AMD ranged from 2.44% (95% CI = 1.85–3.22) in 
people aged 45–49 years to 18.98% (95% CI = 15.05–23.66) in people aged 85–
89 years. Prevalence of early AMD ranged from 1.79% (95% CI = 1.05–3.02) to 
10.05% (95% CI = 6.17–15.97), and, in the case of late AMD, from 0.38% (95% 
CI = 0.16–0.97) to 3.88% (95% CI = 1.68–9.13). In late AMD, the prevalence of 
geographic atrophy (GA) was 0.15% (95% CI = 0.05–0.47) in people aged 45–49 
years and 1.09% (95% CI = 0.35–3.36) in those aged 85–89 years, and the prev-
alence of neovascular AMD (NVAMD) ranged between 0.24% (95% CI = 0.11–
0.50) and 2.79% (95% CI = 1.33–5.77). The number of people with any AMD 
was 12.01 million (95% CI = 9.29–15.46) in 1990 and 26.65 million (95% 
CI = 20.62–34.27) in 2015. Within the same period, the number of people with 
early AMD increased from 9.44 million (95% CI = 7.74–11.15) to 20.91 million 
(95% CI = 17.16–24.68), and those with late AMD rose from 2.58 million (95% 
CI = 1.56–4.30) to 5.74 million (95% CI = 3.46–9.59). In late AMD, the number 
of people living with GA ranged from 0.87 million (95% CI = 0.40–1.83) in 1990 
to 1.93 million (95% CI = 0.89–4.08) in 2015, and NVAMD from 1.71 million 
(95% CI = 1.16–2.47) to 3.81 million (95% CI = 2.57–5.51). The projected num-
ber of people with any AMD in 2020 is 31.23 million (95% CI = 24.18–40.14), 
increasing to 55.19 million (95% CI = 43.04–70.30) in 2050. Between different 
regions, the South Central owed the most AMD cases (5.50 million in 2000 and 
7.52 million in 2010), whereas the North–West China the least (0.66 million in 
2000 and 0.95 million in 2010).
Conclusions The estimates in this study suggest a substantial burden of AMD 
in China, with the ageing process in Chinese society, this burden will be increas-
ing in the foreseen future. Primary and secondary prevention and treatment and 
effective government response are urgently needed. Improved epidemiological 
studies are also required to better develop eye–care strategies and health services.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Age–related macular degeneration (AMD), a degenerative disease of the macula, is a leading cause of se-
vere and irreversible loss of vision globally, and most notably in developed countries [1–3]. In 2010, it 
was estimated that AMD was the third most common cause of blindness, and the fourth leading cause of 
visual impairment worldwide [4]. Although AMD is not a life threatening disorder, up to one–third of the 
affected individuals will experience various degrees of disability and depression during the course of the 
disease, even when only one eye is affected [5,6]. Moreover, AMD is notably associated with falls and 
other injuries, resulting in increased economic and social burden for the individual, caregiver and com-
munity to bear [7–10]. Ageing is consistently documented as the most important risk factor for AMD 
[1,3,10]. In addition, other factors, such as cigarette smoking, female gender, ethnicity, and genetic pre-
disposition may also play a role [3,11,12]. The combined effect of continuous exposure to different risk 
factors and different demographic ageing speed resulted in the global epidemic of AMD showing substan-
tial variation across different ethnic groups and geographic regions [3,13–15].
The clinical course of AMD can be broadly divided into two stages: early and late (advanced) [1,16,17]. 
Early AMD is characterised by soft drusen and/or pigmentary changes, but many early cases do not prog-
ress to the advanced form [16,17]. Late AMD includes two types: geographic atrophy (GA) and neovas-
cular (exudative) AMD (NVAMD). Compared with early AMD, late AMD is far less frequent but most 
damaging to the sight [18]. According to the latest global estimate of AMD prevalence, both early and late 
AMD were most frequent in populations of European ancestry (11.20% and 0.50%). Early AMD is least 
common in Asians (6.81%) while late AMD is least common in populations of African ancestry (0.28%) 
[3]. With Asia having the largest share of the world’s population, and understanding that AMD is an age–
driven disorder, it was estimated that Asia had the greatest number of people with AMD in 2014 (59 mil-
lion). Furthermore, this number is expected to increase at the fastest pace in Asia in comparison to other 
regions – to 113 million by 2040. China, the most populous country in the world, is experiencing the 
most rapid ageing trend among all developing countries. It has been estimated that more than one–third 
of Chinese people living in China will be aged 60 years and over by 2050 [19]. It is, therefore, important 
to have an up–to–date summary of the magnitude and distribution of AMD in the general population to 
inform stakeholders and guide eye–related health policy–making and health services allocation in China.
In the last two decades, an increasing number of epidemiological studies of AMD have been conducted 
in China. The estimates were, however, contingent upon the characteristics of individual studies: the age 
structure of the study sample, case definition and classification of AMD [20–22]. Another important fea-
ture of AMD is that its prevalence is likely to be associated with geographic factors. In the most recent 
global geo–epidemiology analysis of AMD, both latitude and longitude were inversely correlated with 
AMD prevalence, providing a new clue to study the geographic distribution of AMD [15].
Until recently, there were no systematic estimates of AMD prevalence in China. With that said, the sheer 
volume of data available on the prevalence of AMD in Chinese bibliographical databases makes it possible 
to summarise the prevalence and burden of AMD from a modelling perspective [23,24]. Moreover, the 
large territory area with great variation of latitude and longitude in China provides a good opportunity to 
explore the influence of geographic factors within the same country. In this study, we undertook a com-
prehensive systematic review, in both Chinese and English databases, to retrieve population–based stud-
ies of AMD prevalence in China from 1990 onwards. Based on the existing evidence, we estimated and 
projected the prevalence and burden of AMD and its sub–types. The aims of this study were to 1) ascer-
tain the AMD prevalence in China by using epidemiological modelling; 2) estimate and project the over-
all prevalence and number of people living with AMD at the national level from 1990 to 2050; 3) estimate 
the regional prevalence and number of people with AMD from 2000 to 2010.
METHODS
Systematic review
For developing epidemiological models to estimate the prevalence of AMD and its subtypes in the gen-
eral population, a systematic review was conducted by two independent reviewers (PS and YD) in accor-
dance with the Preferred Reporting Items for Systematic reviews and Meta–Analyses (PRISMA) guidelines 
and the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement [25,26]. 
To ensure that all possible informative studies are included, a comprehensive literature search (title, ab-
stract and keywords) was conducted in order to identify relevant studies. First, three Chinese bibliograph-
ic databases and three English bibliographic databases were searched from inception to 17 September 
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2016. These were the China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine 
Literature Database (CBM–SinoMed), PubMed, Embase and Medline. The source of studies in the three 
Chinese databases included journal articles, abstracts, dissertations and conference proceedings, whereas 
those in the three English databases included journal articles only. A combination of search terms for 
prevalence (prevalence, incidence, mortality, morbidity, epidemiology), AMD (age–related macular de-
generation, age–related maculopathy, retina* macula* age related degeneration, retina* macular degen-
eration, macular degeneration) and China (China, Chinese, Hong Kong, Macau, Taiwan) was adopted for 
the comprehensive search. The final search strategy is presented in Table S1 in Online Supplementary 
Document. Note that the search strategy for the different bibliographic databases was slightly different 
based on the database’s specific search features. Snowball searching of reference lists of publications re-
trieved in the first step was then conducted to further identify studies of interest. Only studies published 
since 1990 were retrieved and no language restrictions were imposed.
Only population–based studies that quantified the prevalence of AMD were included in this study. This 
is because studies conducted at institutional sites tend to have poor representativeness of the surround-
ing general population, especially for affected people living in poor and rural areas where access to health 
is not universal. Studies that relied on self–reported diagnosis were also excluded, due to recall bias. Stud-
ies that only reported the number of eyes affected by AMD, rather than the number of affected individu-
als, were also excluded because no prevalence of AMD could be derived from such studies. Duplicate 
publications of the same study were compared and the study providing more details was retained. Some 
additional criteria were also applied to ensure the quality of included studies. The detailed selection cri-
teria are shown in Table 1.
Before reviewing the retrieved records, duplicates were removed manually. Records were screened for rel-
evance in two stages: screening of titles and abstracts followed by the retrieval and check of full–text ar-
ticles. All non–English or non–Chinese language documents were reviewed after translation into English 
by Google Translate. For studies that fulfilled the criteria, three main categories of data were extracted: 
characteristics of the study, characteristics of the investigated population, and prevalence estimates of 
AMD and its subtypes. The data extraction tables were pilot tested on ten randomly selected included 
studies and refined accordingly before the final extraction.
The final data extraction table included:
1)  Characteristics of the study: authors, publication year, study setting, year of survey, sampling method, 
study design (cross–sectional or cohort), AMD assessment method, and AMD grading system;
2)  Characteristics of the investigated population: number of the sample, population type (urban, rural or 
mixed), gender (male, female or mixed), and age (age range, mean or median age, or midpoint of the 
age range);
3)  Prevalence data: number of people with AMD and the number of participants who had been tested, 
by age group, gender, setting and AMD subtype where available.
The geographic indicators of interest (latitude, longitude and average annual insolation) were assigned to 
each study accordingly. The latitude and longitude data were obtained using Google Maps GPS coordi-
nates (http://www.gps–coordinates.net/). The average annual insolation data (ie, the amount of solar ra-
diation incident on the surface of the earth) on the horizontal surface, expressed in kWh/m2/d, was ob-
tained from the National Aeronautics and Space Administration (NASA) Atmospheric Science Data 
Centre (http://eosweb.larc.nasa.gov/sse/). When study settings were defined as larger regions, such as at 
province, or regional levels, the mean centre point of the setting was calculated and the corresponding 
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Table 1. Selection criteria of studies in the systematic review
Inclusion criteria
1) Community–based study of AMD in China (including Hong Kong, Macao and Taiwan)
2) Studies conducted to examine the epidemiology of AMD
3) Studies reported numerical prevalence measure of AMD
Exclusion criteria
1) Multiple publications of the same study
2) Studies with no professional assessment methods or relied on self–reported diagnoses
3)  Studies that were conducted in a population with characteristics that were clearly unrepresentative, eg, visual impaired popu-
lation, diabetes population
4) Studies with inconsistencies between reported methods and presented results
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geographic data of the centre point was used. Studies that reported raw prevalence data in more than one 
geographic area (eg, a single study presented prevalence of AMD for three different cities) were recorded 
separately for each geographic area. For studies that reported aggregated AMD prevalence data for differ-
ent geographic areas, the average geographic data of the different areas were calculated and recorded. For 
studies with missing data of survey year, three years were subtracted from the published year to impute 
the survey year, which was based on the average time from survey to publication in studies with available 
data. In studies where censoring age groups were reported, eg, older than 80 years, the missing age band 
was taken as the same width as other age groups in the same study.
The classification systems used to define AMD and its subtypes include the Wisconsin age–related macu-
lopathy system (WARMGS) [27], the International Classification and Grading system (IC) [28], the Clin-
ical Age–Related Maculopathy Grading System (CARMS) [29], and the “Age–related Macular Degenera-
tion Clinical Diagnosis Standard” proposed by the China Medical Association in 1986 (CMA1986) [30]. 
For studies adopting different classification systems, the prevalence of any AMD, early AMD, late AMD, 
which included GA and NVAMD, was extracted or calculated (if necessary) separately according to the 
definitions below:
1)  Early AMD: any soft drusen (distinct or indistinct) and pigmentary abnormalities, or large soft drusen 
125 μm or more in diameter with a large drusen area (>500 μm diameter circle) or large soft indistinct 
drusen in the absence of signs of late–stage disease;
2)  Late AMD: the presence of geographic atrophy or pigment epithelial detachment, subretinal haemor-
rhage or visible subretinal new vessel, or subretinal fibrous scar or laser treatment scar.
Statistical analysis
Due to high heterogeneity between studies that reported prevalence rates for any AMD, early AMD, late 
AMD, GA and NVAMD (Table S2 in Online Supplementary Document), random–effect models were 
adopted throughout the analysis. In the data extraction process, data were stratified by age, gender and 
setting. Some studies provided more than one data point. To take this hierarchical data structure into ac-
count, a multilevel mixed–effect meta–regression was conducted [31,32]. Given that:
Prevalence p= =
Number of cases
Samle size
Then, the binomial distribution of prevalence rates was transferred to the normal distribution by using 
logit link:
logit p
p
p
odds x x xe e n n   





          log log
1 1 1 2 2
   
Estimates were back transformed and expressed as conventional prevalence:
p 

     
     
e
e
x x x
x x x
n n
n n
   
   
1 1 2 2
1 1 2 21
To develop the overall “envelope” of AMD cases in China from 1990 to 2015, five models were first devel-
oped to establish the prevalence of any AMD, early AMD, late AMD, GA and NVAMD as a function of age:
logit p age      1
Thus, the prevalence of AMD is:
p 

  
  
e
e
age
age
 
 
1
11
The total number of AMD cases (“envelope”) in China was calculated by multiplying the age–specific 
prevalence of AMD for each 5–year age group estimated in the above models with the corresponding 5–
year population subgroups in China, available from the United Nations Population Division (UNPD) [19]. 
This was performed for any AMD, early AMD, late AMD, GA and NVAMD separately in the years 1990, 
2000, 2010 and 2015.
To investigate whether study–level demographic and geographic factors might affect the prevalence of 
AMD, variables of interest were added into the multilevel mixed–effect meta–regression to test the sig-
nificance [33]. As a rule, at least seven data points should be available for each variable [34]. These vari-
ables included gender, setting, latitude, longitude and average annual insolation. Investigation year was 
December 2017  •  Vol. 7 No. 2 •  020703 4 www.jogh.org •  doi: 10.7189/jogh.07.020703
Song et al.
V
IE
W
PO
IN
TS
PA
PE
RS
also tested so as to assess if there were any significant time trends. All variables that individually associ-
ated AMD prevalence in univariable analyses were included in the subsequent multivariable regression 
model, where variables that were not statistically significant were removed, starting from the one with the 
highest p value.
For our projection to the year 2050, age–specific prevalence rates of AMD were assumed to be constant 
over the next 33 years, the number of individuals with AMD from 2020 to 2050 was calculated by mul-
tiplying the age–specific prevalence rates to the UNDP Prospects data [19].
Based on the final multivariable regression models that take the effects of demographic and geographic 
factors into consideration, the estimated national population with AMD was distributed into six geograph-
ical regions, namely, East China, North China, Northeast China, Northwest China, South Central China, 
Southwest China (Table 2) [35–37]. This method was initially proposed by the Child Health Epidemiol-
ogy Reference Group (CHERG), and has, since, been adopted widely in disease burden research [38–40]. 
First, AMD prevalence in each geographic region was calculated, based on the final regression equation. 
Second, the regional population with AMD was estimated by multiplying the regional AMD prevalence 
and corresponding population for the years 2000 and 2010, where regional population data were avail-
able from the fifth and sixth census [36,37]. Finally, the regional population of AMD was adjusted to fit 
the national AMD “envelope”.
Non–dichotomous variables were analysed as continuous. A two–sided p value less than 0.05 was re-
garded as statistically significant for all analyses. All statistical analyses were performed in R Studio (ver-
Table 2. The six geographical regions in China
Region included pRovinces
North China Beijing Municipality, Hebei province, Inner Mongolia Autonomous Region, Shanxi province, Tianjin Mu-
nicipality
Northeast China Heilongjiang province, Jilin province, Liaoning province;
East China Anhui province, Fujian province, Jiangsu province, Jiangxi province, Shandong province, Shanghai Mu-
nicipality, Zhejiang province
South Central China Guangdong province, Guangxi Zhuang Autonomous Region, Hainan province, Henan province, Hubei 
province, Hunan province
Southwest China Chongqing Municipality, Guizhou province, Sichuan province, Tibet Autonomous Region, Yunnan province
Northwest China Gansu province, Ningxia Hui Autonomous Region, Qinghai province, Shaanxi province, Xinjiang Uyghur 
Autonomous Region
Figure 1. Systematic review flow 
diagram. Note: *Reason 1 – Studies 
that were not population–based; 
*Reason 2 – Studies that were not 
based in China; *Reason 3 – Papers 
with no numerical prevalence measure 
of AMD; *Reason 4 – Studies that had 
no professional assessment methods or 
relied on self–reported diagnoses; 
*Reason 5 – Studies that were 
conducted in a population with 
unrepresentative characteristics; 
*Reason 6 – Multiple publications of 
the same study; *Reason 7 – Papers 
with inconsistency between reported 
methods and presented results.
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sion 1.0.136) built on R (version 3.3.0). All included studies in the analysis were 
mapped by ArcGIS software (Version 10.1). The China base map was obtained as 
a shapefile from the Global Administrative Areas (GADM) database (GADM, 2015, 
version 2.0; www.gadm.org).
RESULTS
Summary of systematic review
Figure 1 Shows the process of systematic review for studies included in the final 
meta–analysis. In brief, the initial search identified 2016 citations. After removing 
750 duplications, 986 apparently irrelevant citations by title and abstract review, 
and 15 citations with no sufficient information on methods and results, 265 papers 
were reviewed at the full–text level to assess their eligibility. Ultimately, 25 AMD 
prevalence studies were included in the final analysis.
A full list of included studies is shown in Table S3 in Online Supplementary Doc-
ument, the included data involved 3016 AMD cases in a total of 43 420 examined 
individuals. Table 3 shows the main characteristics of the studies, and the detailed 
characteristics of every study can be found in Table S4 in Online Supplementary 
Document. All included studies were cross–sectional studies that assessed AMD 
by using fundus imaging. Almost half of the retained studies were published in the 
past six years (44.0%), with CMA1986 the most widely adopted grading system 
(48.0%), followed by WARMGS (24.0%) and CARMS (20.0%). The geographic 
distribution of the 25 included studies is demonstrated in Figure 2.
Age–specific prevalence of AMD
In each model (Figure 3), a substantial number of data points were available for 
constructing the relationship between AMD prevalence and age. The age spectrum 
ranged from around 35 years to less than 90 years. However, for GA and NVAMD, 
few data points were available at younger ages (30–40 years). In this study, to en-
sure that the estimated prevalence was comparable, the lower bound of age range 
was set as 45 years and the upper bound as 89 years where data were available for 
model construction at all AMD subtype groups.
Table 3. Main characteristics of the 
included prevalence studies (n = 25)
chaRacteRistics of study numbeR of studies (%)
Year published:
1990–1999 7 (28.0)
2000–2009 7 (28.0)
2010–2016 11 (44.0)
Setting:
Urban 7 (28.0)
Rural 9 (36.0)
Mixed 9 (36.0)
Sample size:
600–1000 5 (20.0)
1001–2000 5 (20.0)
2001–3000 7 (28.0)
3001–5000 4 (16.0)
5001–8000 4 (16.0)
Grading system:
CMA1986* 12 (48.0)
WARMGS† 6 (24.0)
CARMS‡ 5 (20.0)
IC§ 1 (4.0)
Other‖ 1 (4.0)
*CAM 1986 – the “Age–related Macular De-
generation Clinical Diagnosis Standard” pro-
posed by the China Medical Association in 
1986.
†WARMGS – the Wisconsin age–related 
maculopathy system.
‡CARMS, the Clinical Age–Related Macu-
lopathy Grading System.
§IC, the International Classification and 
Grading system.
‖Other, definition in the “Ophthalmology” 
(7th version).
Figure 2. Geographic distribution of the included studies in China.
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Figure 3. Prevalence of age–related macular degeneration (AMD) and its subtypes by age in retained studies. Note: The size of each 
bubble is proportional to the sample size. There were 124 data points for constructing the relation between prevalence and age for 
any AMD, 67 for early AMD, 67 for late AMD, 35 for geographic atrophy (GA) and 54 for neovascular AMD (NVAMD).
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The estimated age–specific prevalence of any AMD, early AMD, late AMD, GA and NVAMD is shown in 
Figure 4 and Table 4. The prevalence of any AMD ranged from 2.44% (95% CI = 1.85–3.22) in people 
aged 45–49 years to 18.98% (95% CI = 15.05–23.66) in people aged 85–89 years. Prevalence of early 
AMD ranged from 1.79% (95% CI = 1.05–3.02) to 10.05% (95% CI = 6.17–15.97), and, in the case of 
late AMD, from 0.38% (95% CI = 0.16–0.97) to 3.88% (95% CI = 1.68–9.13). In late AMD, the preva-
lence of GA was 0.15% (95% CI = 0.05–0.47) in people aged 45–49 years and 1.09% (95% CI = 0.35–
3.36) in those aged 85–89 years, and the prevalence of NVAMD ranged between 0.24% (95% CI = 0.11–
0.50) and 2.79% (95% CI = 1.33–5.77).
National population affected with AMD from 1990 to 2015
By applying the age–specific prevalence of AMD to the national population in 1990, 2000, 2010 and 
2015, the number of people living with AMD in China was estimated (Table S5 in Online Supplemen-
tary Document). During this period, the national prevalence of any AMD slightly decreased by 0.41%, 
from 5.26% (95% CI = 4.07–6.76) in 1990 to 5.24% (95% CI = 4.05–6.73) in 2015. This declining trend 
was also witnessed in early AMD and late AMD, with decreasing rates of 0.50% and 0.07% respectively. 
In late AMD, GA also showed a decreasing trend within this time frame, whereas the prevalence of NVAMD 
increased slightly (Table 5). Despite this decreasing prevalence trend during 1990–2015, the overall num-
ber of people with any AMD or its subtypes all increased dramatically due to the rapidly ageing popula-
tion. The national number of people with any AMD increased by 121.80%, from 12.01 million (95% 
CI = 9.29–15.46) in 1990 to 26.65 million (95% CI = 20.62–34.27) in 2015. Within the same period, the 
number of people with early AMD increased from 9.44 million (95% CI = 7.74–11.15) to 20.91 million 
(95% CI = 17.16–24.68), and those with late AMD rose from 2.58 million (95% CI = 1.56–4.30) to 5.74 
million (95% CI = 3.46–9.59), which yielded increasing rates of 121.60% and 122.55% respectively. In 
late AMD, increase in the number of people living with GA was similar to those with NVAMD (121.99% 
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Table 4. Estimated age–specific prevalence (% and 95% confidence interval) of age–related macular degeneration 
(AMD) and its subtypes in China
age (yeaRs) any amd eaRly amd late amd ga nvamd
45–49 2.44 1.79 0.38 0.15 0.24
(1.85–3.22) (1.05–3.02) (0.16–0.97) (0.05–0.47) (0.11–0.50)
50–54 3.21 2.23 0.51 0.19 0.32
(2.45–4.19) (1.32–3.74) (0.22–1.24) (0.06–0.58) (0.16–0.67)
55–59 4.20 2.78 0.68 0.24 0.44
(3.22–5.45) (1.67–4.62) (0.30–1.60) (0.08–0.72) (0.22–0.89)
60–64 5.47 3.47 0.91 0.31 0.60
(4.23–7.06) (2.09–5.71) (0.41–2.09) (0.11–0.90) (0.30–1.19)
65–69 7.11 4.31 1.22 0.40 0.82
(5.52–9.12) (2.61–7.05) (0.55–2.76) (0.14–1.15) (0.41–1.60)
70–74 9.20 5.36 1.63 0.52 1.11
(7.17–11.72) (3.26–8.68) (0.74–3.67) (0.18–1.48) (0.56–2.19)
75–79 11.81 6.63 2.18 0.66 1.52
(9.26–14.96) (4.05–10.68) (0.98–4.94) (0.23–1.93) (0.76–3.01)
80–84 15.05 8.18 2.91 0.85 2.06
(11.85–18.92) (5.01–13.09) (1.29–6.70) (0.28–2.54) (1.01–4.16)
85–89 18.98 10.05 3.88 1.09 2.79
(15.05–23.66) (6.17–15.97) (1.68–9.13) (0.35–3.36) (1.33–5.77)
GA – geographic atrophy, NVAMD – neovascular AMD
Table 5. Estimated prevalence and number of people living with age–related macular degeneration (AMD) in China 
from 1990 to 2015, by AMD type
amd type pRevalence of amd (%, 95% ci) numbeR of people with amd (million, 95% ci) Rate of change (%, 1990–2015)
1990 2015 1990 2015 prevalence AMD cases
Any AMD 5.26 5.24 12.01 26.65 –0.41 121.80
(4.07–6.76) (4.05–6.73) (9.29–15.46) (20.62–34.27)
Early AMD 4.13 4.11 9.44 20.91 –0.50 121.60
(3.39–4.88) (3.37–4.85) (7.74–11.15) (17.16–24.68)
Late AMD 1.13 1.13 2.58 5.74 –0.07 122.55
(0.68–1.88) (0.68–1.88) (1.56–4.30) (3.46–9.59)
GA 0.38 0.38 0.87 1.93 –0.33 121.99
(0.17–0.80) (0.17–0.80) (0.40–1.83) (0.89–4.08)
NVAMD 0.75 0.75 1.71 3.81 0.05 122.84
(0.51–1.08) (0.51–1.08) (1.16–2.47) (2.57–5.51)
GA – geographic atrophy, NVAMD – neovascular AMD
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Figure 4. Estimated age–specific prevalence of age–related macular degeneration (AMD) and its subtypes in China, 
with 95% confidence intervals. GA – geographic atrophy, NVAMD – neovascular AMD.
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vs 122.84%), which ranged from 0.87 million (95% CI = 0.40–1.83) to 1.93 million (95% CI = 0.89–4.08), 
and 1.71 million (95% CI = 1.16–2.47) to 3.81 million (95% CI = 2.57–5.51) throughout this time frame 
respectively (Table 5). In 2015, the age group that contributed the most cases of any AMD, early AMD, 
late AMD, GA and NVAMD was 60–64 years (Figure 5).
Effects of demographic and geographic factors on the prevalence of AMD
Findings from the univariable meta–regression analyses (Table S6 in Online Supplementary Document) 
showed that age, setting and latitude were significantly associated with the prevalence of any AMD. For 
early AMD, age, gender, setting and latitude also had a significant influence on the prevalence. For late 
AMD, age and latitude were found to be significantly associated with the prevalence. However, in late 
AMD, only age was found to be significantly associated with the prevalence of GA, and age, gender, lati-
tude and insolation were significantly associated with the prevalence of NVAMD. For any AMD and all 
subtypes, the investigation year was identified to have no influence on prevalence rates and increased age 
was the only constantly significant risk factor.
Although most studies provided multiple data points of prevalence rates, these data were mainly strati-
fied by age groups. For AMD subtype groups (early AMD, late AMD, GA and NVAMD), and after con-
trolling the difference of age structures, insufficient data were available for conducting multivariable meta–
regression that simultaneously included all statistically significant factors identified in the univariable 
analyses. Thus, here the multivariable regression model was only conducted and reported for any AMD. 
The formula generated from the multivariable regression is shown below:
logit p age setting setrural          4 230 0 056 0 6013 0 053. . . . ting latitudeurban   0 060.
Where p indicates the prevalence of any AMD; setting
rural
 = 1 for rural setting and = 0 otherwise; setting
ur-
ban
 = 1 for urban setting and = 0 otherwise; latitude refers to the absolute value of latitude.
Projection of national population affected with AMD from 2020 to 2050
No secular trend of the prevalence of any AMD, early AMD, late AMD, GA and NVAMD was observed in 
the included studies, thus age–specific prevalence was assumed as constant for the projection analysis. 
By applying the age–specific prevalence of AMD to the national population in 2020, 2030, 2040 and 
2050, the number of people with AMD was estimated (Tables S5 in Online Supplementary Document). 
Unlike the slightly fluctuating trend of AMD prevalence during 1990 to 2015, the prevalence rates of all 
subtypes of AMD will increase notably during 2020 and 2050. In 2020, the prevalence of any AMD will 
be 5.39% (95% CI = 4.18–6.93) and is expected to increase by 41.66%, reaching to 7.64% (95% CI = 5.96–
9.73) in 2050. Among all subtypes of AMD, NVAMD will show the greatest increasing rate of 57.48%, 
from 0.78% (95% CI = 0.52–1.12) in 2020 to 1.22% (95% CI = 0.83–1.75) in 2050, whereas the increas-
ing rate of early AMD will be the smallest (38.45%), from 4.23% (95% CI = 3.47–4.99) to 5.21% (95% 
CI = 4.31–6.08) during this period (Table 6).
Figure 5. Estimate of the national number of people with age–related macular degeneration (AMD) and contributing age groups in 
China from 1990 to 2015, by AMD type. GA – geographic atrophy, NVAMD – neovascular AMD.
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Table 6. Projected prevalence and number of people living with age–related macular degeneration (AMD) in China 
from 2020 to 2050, by AMD type
amd type pRevalence of amd (%, 95% ci) numbeR of people with amd (million, 95% ci) Rate of change (%, 2020–2050)
2020 2050 2020 2050 prevalence AMD cases
Any AMD 5.39 7.64 31.23 55.19 41.66 76.72
(4.18–6.93) (5.96–9.73) (24.18–40.14) (43.04–70.30)
Early AMD 4.23 5.85 24.47 42.26 38.45 72.71
(3.47–4.99) (4.87–6.79) (20.10–28.87) (35.15–49.05)
Late AMD 1.17 1.79 6.76 12.92 53.28 91.21
(0.70–1.95) (1.09–2.94) (4.08–11.28) (7.89–21.26)
GA 0.39 0.57 2.26 4.09 44.92 80.78
(0.18–0.83) (0.26–1.19) (1.04–4.78) (1.89–8.59)
NVAMD 0.78 1.22 4.50 8.84 57.48 96.45
(0.52–1.12) (0.83–1.75) (3.04–6.50) (6.00–12.66)
GA – geographic atrophy, NVAMD – neovascular AMD
From 2020 to 2050, the number of cases of any AMD in China will rise by 76.72%, from 31.23 million 
(95% CI = 24.18–40.14) to 55.19 million (95% CI = 43.04–70.30). The increasing rate of late AMD cases 
will be greater than early AMD cases (91.12% vs 72.70%), with the number of people affected by early 
AMD increasing from 24.47 million (95% CI = 20.10–28.87) in 2020 to 42.26 million (95% CI = 35.15–
49.05) in 2050, and those affected by late AMD from 6.76 million (95% CI = 4.08–11.28) to 12.92 mil-
lion (95% CI = 7.89–21.26). In late AMD, the number of people with GA will increase by 80.78%, from 
2.26 million (95% CI = 1.04–4.78) in 2020, to 4.09 million (95% CI = 1.89–8.59) in 2050. Furthermore, 
the number of those with NVAMD will grow even further (96.45%), from 4.50 million (95% CI = 3.04–
6.50) to 8.84 million (95% CI = 6.00–12.66) (Table 6). From 2020 to 2050, the age groups to contribute 
the most cases will shift from 65–69 years to 80–84 years for any AMD, late AMD, GA and NVAMD, and 
from 65–69 years to 75–79 years for early AMD (Figure 6).
Regional population affected with AMD from 2000 to 2010
The total number of AMD cases in China in 2000 and 2010 was distributed across the six geographical 
regions according to the final multivariable model that took into account three main factors: age, setting 
and latitude. In 2000, the national prevalence of AMD in China was 5.16% (95% CI = 3.99–6.64), with 
the regional prevalence estimates ranging from 2.69% (95% CI = 1.67–4.29) in North–East China to 6.64% 
(95% CI = 5.12–8.52) in South Central China. In 2010, the prevalence was still the highest in South Cen-
tral China (6.74% [95% CI = 5.20–8.65]) and the lowest in North–East China (2.65% [95% CI = 1.66–
4.20]), with the overall prevalence in Chinese population increasing to the level of 5.24% (95% CI = 4.05–
6.73). During 2000 to 2010, the overall prevalence of AMD increased by 1.44%, and the most marked 
Figure 6. Projection of the national number of people with age–related macular degeneration (AMD) and contributing age groups in 
China from 2020 to 2050, by AMD type. GA – geographic atrophy, NVAMD – neovascular AMD.
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Table 7. Estimated prevalence and number of people living with any age–related macular degeneration (AMD) in 
China in the years 2000 and 2010, by geographical region
Region pRevalence of amd (%, 95% ci) numbeR of people with amd (million, 95% ci) Rate of change (%, 2000–2010)
2000 2010 2000 2010 prevalence AMD cases
North China 3.28 3.36 1.23 1.82 2.40 48.18
(2.35–4.55) (2.42–4.64) (0.88–1.70) (1.31–2.51)
North–East China 2.69 2.65 0.76 1.11 –1.37 46.70
(1.67–4.29) (1.66–4.20) (0.47–1.21) (0.69–1.76)
East China 5.46 5.57 5.32 7.33 1.99 37.67
(4.39–6.74) (4.49–6.86) (4.29–6.57) (5.91–9.04)
South Central China 6.64 6.74 5.50 7.52 1.54 36.74
(5.12–8.52) (5.20–8.65) (4.24–7.05) (5.80–9.64)
South–West China 5.68 6.05 2.85 3.70 6.51 29.97
(4.50–7.11) (4.81–7.56) (2.26–3.56) (2.94–4.62)
North–West China 3.29 3.40 0.66 0.95 3.23 44.65
(2.44–4.43) (2.53–4.55) (0.49–0.89) (0.71–1.28)
China 5.16 5.24 16.31 22.43 1.44 37.50
(3.99–6.64) (4.05–6.73) (12.62–20.99) (17.36–28.85)
increase was in Southwest China (6.51%) while the prevalence rate of AMD declined by 1.37% in North–
East China (Table 7).
Estimates of the number of people living with AMD in different regions are shown in Table 7 and Figure 
7. With the ageing trend of the Chinese population, the total number of people living with AMD in Chi-
na increased by 37.50%, from 16.31million (95% CI = 12.62–20.99) in 2000 to 22.43 million (95% 
CI = 17.36–28.85) in 2010. In 2000, more than one–third (33.72%) of Chinese AMD cases were found 
living in South Central China (5.50 million, 95% CI = 4.24–7.05]) and only 4.05% were in North–West 
China (0.66 million, 95% CI = 0.49–0.89). In 2010, this distribution of AMD cases remained the same 
across the six geographical regions, with most (33.53%) of the AMD cases in South Central China (7.52 
million, 95% CI = 4.24–7.05) and the least (4.24%) in North–West China (0.95 million, 95% CI = 0.71–
1.28]). From 2000 to 2010, the most striking increases in the number of AMD cases were in North Chi-
na (48.64%) and North–East China (47.06%), and the least in South–West China (29.97%). Throughout 
this decade, the age groups that contributed the most AMD cases shifted from 55–59 years to 60–64 years 
in all of the six regions.
Figure 7. Estimate of the regional number of people with age–related macular degeneration (AMD) and contribut-
ing age groups in China in the years 2000 and 2010.
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DISCUSSION
In this systematic review and meta–analysis, data–driven estimates and projections of AMD prevalence 
and burden in China were presented, both at the national level and at the regional levels. The results from 
this synthesised population–based data show that the burden of AMD in China is substantial. From 1990 
to 2015, the prevalence of AMD fluctuated at around 5.2%, which translates to a total of 26.65 million 
affected individuals in 2015. By 2050, prevalence of AMD is expected to increase to 7.64%, with the cor-
responding number of affected individuals being 55.19 million. Substantial regional variation was found 
across the country, with AMD prevalence being the highest in South Central China and the lowest in the 
North–East. In terms of the total number of AMD cases, the greatest burden was in the South Central 
area, and the smallest in North–West China.
To the best of our knowledge, this study is the first attempt to estimate the prevalence and the burden of 
AMD in China and to make future projections. The comprehensive search strategies and strict inclusion 
and exclusion criteria ensured a well–designed analysis. Furthermore, the current study provided esti-
mates of the prevalence and the number of affected AMD cases by AMD subtype, with this additional in-
formation being of particular clinical and public health relevance. Indeed, such information offers valu-
able, detailed insights into the burden of AMD in China. Critically, this study used the best available data 
to portray a complete picture of the public health burden of AMD in different regions. Therefore, it can 
serve as the basis for health policy making and resource allocation for AMD prevention and treatment 
initiatives. From a global perspective, this study complements the most recent Global AMD study, where 
insufficient data were available for national estimates and projections [3].
However, this study is not free from limitations. First, significant heterogeneity existed between all of the 
included studies, despite the strict inclusion and exclusion criteria applied. Like any meta–analysis, the 
findings of this study are only as good as the included primary investigations. Included studies did not 
come from across the country, thus the ability to generate provincial estimates of AMD prevalence and 
cases may be limited. Second, one NVAMD–like disease, polypoidal choroidal vasculopathy, is markedly 
more common in Asians [3,41,42], and taking into consideration that most population–based studies 
may have limited ability to distinguish between these two diseases (as suggested previously [3]), the prev-
alence and burden of NVAMD in the current study may be overestimated. In addition, as suggested by a 
previous meta–analysis, studies using fundus imaging with classifications, rather than the internationally 
recognised grading systems, are more likely to diagnose late AMD [13]. In this study, almost half of the 
included studies adopted the grading system proposed by the Chinese Medical Association, which may 
also have contributed to the peculiarly elevated prevalence rate of late AMD. A further point to raise is 
that only a limited set of variables were included and explored in the meta–regression analysis. This means 
that there could have also been further explanatory variables that may influence the presence of AMD. 
Moreover, the included demographic and geographic variables were mainly aggregate level data, and al-
though efforts were made to extract data stratified by age, gender and location, the variation at the indi-
vidual level may still be hidden. This may include smoking exposure, the habit of wearing sunglasses, 
and others. A further limitation of the study is that the estimates of regional prevalence and burden of 
AMD were based on the assumption that the pooled prevalence estimate for a specific region was homo-
geneous across all included provinces within this region, but this is quite unrealistic. Additionally, for re-
gions that contributed only a few, or no actual AMD prevalence data points to the model, the model–based 
estimates may diverge quite considerably from the true prevalence. Finally, as reported in both previous 
reviews and substantiated in the current study, the prevalence of AMD and all its subtypes was stable over 
time [3,13]. Based on this assumption, the projections of the national prevalence and burden of AMD 
were actually based on the model–based age–specific prevalence and demographic changes during the 
next three decades. Thereby, the uncertainty of these projections may be largely dependent on the accu-
racy of age–specific prevalence model and the UNPD population projection. Bearing these limitations in 
mind, estimates presented in the current study should be interpreted judiciously.
In this study, the overall prevalence of AMD among the Chinese population was lower than the estimates 
in the Global AMD study, which reported an overall AMD prevalence of 6.86% in people living in Asia 
[3]. In the Global AMD study, the prevalence estimates for Asia were based on eleven studies conducted 
across Asia, among which, six came from south Asia (India, Singapore, and Thailand), three from China 
and two from Japan. Given the fact that AMD prevalence increases with decreasing latitude, as detected 
in both this study and a previous global geo–epidemiology study of AMD [15], it is not surprising that 
the overall prevalence of AMD in the current study is lower than that in Asia – as estimated by the Glob-
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al AMD study. Moreover, the eleven studies in the Global AMD study were each published in the 21st 
century, whereas those included in this study distributed from 1990 to 2014. Although no secular trend 
of AMD was detected in either the Global AMD study or this study, the difference of the estimated AMD 
prevalence in these two studies can still be partly explained by the difference of ageing demographic struc-
ture [3,13,15].
In line with previous population–based investigations and synthesised analysis [3,14,43], this study con-
firms two common notions of AMD with strong evidence. First, AMD is a degenerative and progressive 
disease, with the prevalence of AMD dramatically increasing with age, and with age also found to be the 
only constant risk factor in the presence of any AMD and all its subtypes. Second, the prevalence of early 
AMD was found to be much higher than that of late AMD. This finding, however, should not be misinter-
preted as late AMD contributing a smaller burden. Rather, most individuals with early AMD may not go 
on to develop the late–stage disease, and late AMD is a much more severe disease than early AMD [9,13]. 
In this study, the prevalence of late AMD in Chinese people in 2015 was found to be even higher than that 
of people living in Europe (1.13% vs 0.75), the continently highest prevalence of both early and late AMD 
as revealed by the Global AMD study [3]. In view of the large population size in China, this striking find-
ing highlights an urgent need for action on the prevention and treatment of late AMD, given its clinical 
significance. Compared to GA, the group of NVAMD represents a larger burden in Chinese population be-
cause the prevalence and number of people with NVAMD were estimated as around twice higher than 
those of GA. This phenomenon has been reported in some individual investigations [44,45], although it 
has not been universally acknowledged [13]. This finding is still of particular importance for the second-
ary prevention, especially for NVAMD, whose progress to sight loss could be slowed considerably by cur-
rent treatment approaches – such as the use of anti–vascular endothelial growth factor agents [46,47].
In this study, AMD was found to be more prevalent in urban populations than in rural populations, with 
possible explanations for this disparity being the difference in environments (eg, UV exposure), as well 
as lifestyles (eg, education, profession and level of physical activity). While it is not possible to say pre-
cisely what the determinants are, this study clearly shows that people living in rural areas with a self–sus-
tained economy are less likely to be affected by AMD [48,49].
A gradient of decreasing prevalence of AMD was noted in increasing latitude, which suggests that the spe-
cial climate and environmental factors in geographical areas approximating the equator may accelerate 
the development of AMD. One common hypothesis is that AMD is associated with the amount of insola-
tion [15]. However, the indicator of average annual insolation was only found to be significantly associ-
ated with late AMD in this present study. There are two possible reasons for this. First, annual insolation 
data were averaged over a 22–year period (July 1983 – June 2005), which may represent a considerable 
time–lag [50,51]. Second, the relation between insolation and the prevalence of AMD may not be a mono-
tone function, the global geo–epidemiology study of AMD revealed higher prevalence rates of AMD in 
locations with insolation ≤3 kWh/m2/d compared with those with insolation >3 kWh/m2/d [15]. Although 
this interesting relation was not studied further because of limited data availability, the negative relation 
between latitude and AMD prevalence is an interesting hypothesis to explore in future Chinese AMD ep-
idemiological studies.
Male gender was indicated as a risk factor for early AMD and NVAMD in the univariable regression anal-
ysis of this study. This is in contrast to previous reviews and individual investigations of populations of 
European ancestry, where females were reported to have a higher risk of developing NVAMD [13,45,52]. 
However, this study is underpowered to further confirm the observed gender difference in multivariable 
regression analysis. In the multivariable analysis of the prevalence of any AMD, no evidence of gender 
difference was found after adjusting for a priori demographic and geographic variables. This finding is 
consistent with the previous Global AMD study [3].
Variation in AMD prevalence and burden was noted in different geographic locations in China. The vari-
ation was mainly driven by the different demographic structures and the intrinsic environmental charac-
teristics of these regions. According to the estimates for the six regions, AMD epidemics continue to be 
concentrated in the most populous South Central China. Taken together, these findings are of a particu-
lar public health interest in national health service allocation. Based on this study, more epidemiological 
investigations are required in order to make the regional estimates of subtypes of AMD in the future.
This work has important implications both in academic and public health areas. Future epidemiological 
studies of AMD in China would benefit from greater standardisation and improved design, ideally adopt-
ing internationally recognised grading systems and presenting results for different subtypes. In addition, 
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such as Tibet. From the national perspective, the public health impact of AMD is not only limited to the 
number of people affected, but also brings about multiple diagnostic and treatment challenges arising 
from this condition [53,54]. It is prudent to address the importance of primary prevention, such as smok-
ing cessation [11,55], lifestyle modification, antioxidant therapy [56], and the use of hats and sunglasses 
[57]. In the meanwhile, the treatment of NVAMD is already available (although rather expensive) 
[47,58,59]. Given the remarkable potential economic burden on the society, government efforts must be 
taken to ensure the availability of health services to address AMD from the points of diagnosis and treat-
ment, and even prevention when available.
To conclude, this systematic review and meta–analysis provides the first comprehensive and up–to–date 
estimate of AMD prevalence and burden in China. The results from this study indicate that the burden 
of AMD is substantial in China, with great variance among different subtypes and geographic regions. In 
the next decade and beyond, the ageing demographic will make this burden even larger. Improved epi-
demiological studies are still needed to inform optimal implementation of eye care programmes in China.
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